AbCellera Stock – Turning Antibodies Into Drugs

We believe it’s critically important to only invest in businesses that we understand. If you need a subject matter expert to explain a company’s value proposition, you shouldn’t be invested in it. Yesterday’s article on A Pure-Play LegalTech Stock for FinTech Investors is a great example of a value proposition that’s easy to understand. Today, we’re going to talk about a company that’s not so easy to understand – AbCellera (ABCL).

The AbCellera IPO

Figuring out which life sciences stocks to write about here at Nanalyze isn’t easy. We monitor all initial public offerings (IPOs) that are announced and make quick decisions on what to cover. When AbCellera filed their IPO late last year, we were undecided on whether or not to cover it. On one hand, they’re a full-stack, AI-powered drug discovery platform which is right up our alley. On the other hand, their business model isn’t very easy to understand. Our screener at the time thought they were pushing